NCT07935109 Management of Severe Plasmodium Falciparum Malaria With Oral Artemisinin Derivatives
| NCT ID | NCT07935109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier de Saint-Denis |
| Condition | Malaria, Falciparum |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-07-15 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2026-07-15 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ACTs could be used as first-line treatment for Plasmodium falciparum malaria without clinical signs of severity but with biological severity criteria. The study aims to determine the real-world frequency of ACT monotherapy use in cases of P. falciparum malaria with severity criteria, and to compare the treatment success of ACTs with that of artesunate.
Eligibility Criteria
Inclusion Criteria * Patients aged 18 years or older. * Diagnosis of Plasmodium falciparum malaria. * At least one clinico-biological criterion of severe malaria. * Hospitalization in a medical intensive care/critical care unit. * Hospitalization between January 1, 2011 and October 30, 2025. Exclusion Criteria * Age \<18 years. * Patient who objects to the use of their data for research.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07935109 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malaria, Falciparum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07935109 currently recruiting?
Yes, NCT07935109 is actively recruiting participants. Contact the research team at nolan.hassold@ch-stdenis.fr for enrollment information.
Where is the NCT07935109 trial being conducted?
This trial is being conducted at Saint-Denis, France.
Who is sponsoring the NCT07935109 clinical trial?
NCT07935109 is sponsored by Centre Hospitalier de Saint-Denis. The trial plans to enroll 1,000 participants.